Compound EGFR mutations are predominantly PACC (P-loop and alpha-C helix compressing) mutations with increased responsiveness to second- vs third-generation tyrosine kinase inhibitors
A common lung cancer mutation pattern responds equally well to standard targeted drugs, helping doctors avoid treatment delays from misclassification.
Analysis of 15,851 cfDNA-tested NSCLC samples and 1,542 clinical patients established that EGFR PACC mutations predominantly occur as compound in-cis mutations (66.2%), unlike classical or exon 20 mutations, and that compound PACC mutations retain identical second-generation TKI treatment superiority as single PACC mutations. These findings provide directly actionable treatment selection guidance for a potentially underrecognized and misclassified molecular subgroup of NSCLC.
What the study was
- Study design
- Multi-cohort retrospective analysis with in vitro validation
- Population
- EGFR-mutant NSCLC patients; cfDNA-tested samples (Guardant Health) and real-world clinical cohorts
- Sample size
- 15851
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of Thoracic Oncology
Why it surfaced
Large-scale cfDNA characterization of compound EGFR PACC mutations with immediate clinical actionability: patients with PACC single or compound mutations should receive second-generation TKIs; addresses misclassification risk in current clinical practice; MD Anderson + Guardant collaboration
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.